Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis

Experimental Hematology

Volumn 34, Issue 11, 2006, Pages 1496-1504

  Kawahara, Masahiro ^a   Hori, Toshiyuki ^a   Matsubara, Yasushi ^a   Okawa, Katsuya ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLVALYLMETHIONYLASPARTYLASPARAGINYLLYSYLASPARAGINYLPROLYLTHREONYL ISOLEUCYLLYSINE; ARGINYLGLUTAMINYLGLUTAMINYLASPARTYLALANYLALANYLLEUCYLPHENYL ALANYLLYSYLALANYLTRYPTOPHAN; ASPARTYLISOLEUCYLLYSYLPROLYLSERYLASPARAGINYLISOLEUCYLPHENYL ALANYLISOLEUCYLSERYLARGININE; GLUTAMINYLVALYLVALYLTYROSYLARGINYLPHENYLALANYLTHREONYLALANYLARGININE; GLUTAMYLVALYLASPARAGINYLGLUTAMYLALANYLALANYLLEUCYLLEUCYLTHREONINE; GLYCYLGLUTAMYLHISTIDYLLEUCYLHISTIDYLLEUCYLGLUTAMINYLTHREONYLPROLINE; HISTIDYLPROLYLARGINYLSERYLPROLYLTHREONYLPROLYLTHREONYLLEUCINE; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B62 ANTIGEN; PEPTIDE DERIVATIVE; SERYLGLUTAMYLALANYLARGINYLTHREONYLLEUCYLISOLEUCYLTHREONYLPHENYLALANINE; SERYLGLUTAMYLPHENYLALANYLGLYCYLTHREONYLVALYLTHREONYLARGINYLPHENYLALANINE; SERYLISOLEUCYLPHENYLALANYLASPARTYLGLYCYLARGINYLVALYLVALYLALANINE; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG IDENTIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSED PHASE LIQUID CHROMATOGRAPHY; T CELL LEUKEMIA;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CYTOTOXICITY TESTS, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MASS SPECTROMETRY; MICROTUBULE-ASSOCIATED PROTEINS; PEPTIDE FRAGMENTS; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33749606409     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.06.010     Document Type: Article

References (48)

1. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., and Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50 (1977) 481-492
2. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 15 (1997) 15-37
3. Yamada Y., Tomonaga M., Fukuda H., et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113 (2001) 375-382
4. Okamura J., Utsunomiya A., Tanosaki R., et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105 (2005) 4143-4145
5. Kami M., Hamaki T., Miyakoshi S., et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol 120 (2003) 304-309
6. Shimamoto Y., Kikuchi M., Funai N., Suga K., Matsuzaki M., and Yamaguchi M. Spontaneous regression in adult T-cell leukemia/lymphoma. Cancer 72 (1993) 735-740
7. Tjoa B.A., Simmons S.J., Bowes V.A., et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36 (1998) 39-44
8. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95 (2000) 286-293
9. Osman Y., Takahashi M., Zheng Z., et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13 (1999) 166-174
10. Arai J., Yasukawa M., Ohminami H., Kakimoto M., Hasegawa A., and Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97 (2001) 2903-2907
11. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
12. Chen Y.T., Scanlan M.J., Sahin U., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94 (1997) 1914-1918
13. Van den Eynde B., Peeters O., De Backer O., Gaugler B., Lucas S., and Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182 (1995) 689-698
14. Harashima N., Kurihara K., Utsunomiya A., et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 64 (2004) 391-399
15. *1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. J Virol 79 (2005) 10088-10092
16. Taylor G.P., and Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24 (2005) 6047-6057
17. Hishizawa M., Imada K., Sakai T., Ueda M., Hori T., and Uchiyama T. Serological identification of adult T-cell leukaemia-associated antigens. Br J Haematol 130 (2005) 382-390
18. Weinschenk T., Gouttefangeas C., Schirle M., et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62 (2002) 5818-5827
19. Ramakrishna V., Ross M.M., Petersson M., et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 15 (2003) 751-763
20. Maeda M., Arima N., Daitoku Y., et al. Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. Blood 70 (1987) 1407-1411
21. Katoh T., Harada T., Morikawa S., and Wakutani T. IL-2- and IL-2-R- independent proliferation of T-cell lines from adult T-cell leukemia/lymphoma patients. Int J Cancer 38 (1986) 265-274
22. Falk K., Rotzschke O., Stevanovic S., Jung G., and Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351 (1991) 290-296
23. Barnstable C.J., Bodmer W.F., Brown G., et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14 (1978) 9-20
24. Kageyama G., Kawano S., Kanagawa S., et al. Effect of mutated transporters associated with antigen-processing 2 on characteristic major histocompatibility complex binding peptides: analysis using electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 18 (2004) 995-1000
25. Matsubara Y., Hori T., Morita R., Sakaguchi S., and Uchiyama T. Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells. Leukemia 19 (2005) 482-483
26. Carre P.C., Mortenson R.L., King Jr. T.E., Noble P.W., Sable C.L., and Riches D.W. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest 88 (1991) 1802-1810
27. Morita R., Ukyo N., Furuya M., Uchiyama T., and Hori T. Atrial natriuretic peptide polarizes human dendritic cells toward a Th2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor A. J Immunol 170 (2003) 5869-5875
28. + T cell clones. J Immunol 148 (1992) 738-745
29. - thymocytes highly purified from postnatal thymus. J Immunol 146 (1991) 2116-2121
30. Storkus W.J., Alexander J., Payne J.A., Dawson J.R., and Cresswell P. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A 86 (1989) 2361-2364
31. Lecoeur H., Fevrier M., Garcia S., Riviere Y., and Gougeon M.L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253 (2001) 177-187
32. Grossman W.J., Verbsky J.W., Tollefsen B.L., Kemper C., Atkinson J.P., and Ley T.J. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104 (2004) 2840-2848
33. Odreman F., Vindigni M., Gonzales M.L., et al. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 4 (2005) 698-708
34. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103 (2006) 2794-2799
35. Brossart P., Stuhler G., Flad T., et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58 (1998) 732-736
36. Sarkar A.K., and Nuchtern J.G. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 60 (2000) 1908-1913
37. Mocellin S., Mandruzzato S., Bronte V., Lise M., Nitti D., and Part I. Vaccines for solid tumours. Lancet Oncol 5 (2004) 681-689
38. Laheru D., and Jaffee E.M. Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer 5 (2005) 459-467
39. Oka Y., Tsuboi A., Taguchi T., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101 (2004) 13885-13890
40. Ikeda H., Lethe B., Lehmann F., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
41. Matsushita M., Ikeda H., Kizaki M., et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 112 (2001) 916-926
42. Greiner J., Ringhoffer M., Taniguchi M., et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 108 (2004) 704-711
43. Steinbach D., Hermann J., Viehmann S., Zintl F., and Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133 (2002) 118-123
44. *)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193 (2001) 73-88
45. Li L., Reinhardt P., Schmitt A., et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 54 (2005) 685-693
46. Montini E., Andolfi G., Caruso A., et al. Identification and characterization of a novel serine-threonine kinase gene from the Xp22 region. Genomics 51 (1998) 427-433
47. Charrasse S., Mazel M., Taviaux S., Berta P., Chow T., and Larroque C. Characterization of the cDNA and pattern of expression of a new gene over-expressed in human hepatomas and colonic tumors. Eur J Biochem 234 (1995) 406-413
48. Kim I.G., Jun D.Y., Sohn U., and Kim Y.H. Cloning and expression of human mitotic centromere-associated kinesin gene. Biochim Biophys Acta 1359 (1997) 181-186